Operative data.

This study aimed to evaluate the safety and efficacy of a modified, bloodless Del Nido (DN) cardioplegia solution in patients undergoing isolated aortic valve replacement (AVR). A total of 370 patients who underwent isolated AVR between 2015 and 2022 were retrospectively analyzed. Patients were categorized into two groups based on the cardioplegia solution used: the bloodless DN group (N = 180) and the histidine-tryptophan-ketoglutarate (HTK) group (N = 190). To reduce selection bias and adjust for baseline differences, inverse probability of treatment weighting analysis was performed. There was no significant difference in in-hospital mortality between the two groups (HTK vs. DN: 1.2% vs. 0.9%, P = 0.554). However, the rate of spontaneous sinus rhythm restoration without the need for defibrillation following aortic cross-clamp release was significantly higher in the DN group (40.0% vs. 75.2%, P本研究旨在评估改良无血Del Nido（DN）心脏停搏液在接受单纯主动脉瓣置换术（AVR）患者中的安全性与有效性。本研究回顾性分析了2015年至2022年间共370例接受单纯AVR的患者。根据所使用的心脏停搏液类型，将患者分为两组：无血DN组（N=180）与组氨酸-色氨酸-酮戊二酸（HTK）组（N=190）。为降低选择偏倚并校正基线差异，本研究开展了治疗加权逆概率分析。两组患者的住院死亡率无显著差异（HTK组vs. DN组：1.2% vs. 0.9%，P=0.554）。然而，在主动脉阻断钳松开后无需除颤即可实现自发窦性心律恢复的比例方面，DN组显著更高（40.0% vs. 75.2%，P